Motor symptom asymmetry is a defining clinical feature of PD. Our routine clinical practice is to treat the most severely affected hemibody with unilateral DBS, followed by staged surgery on the opposite side of the brain (when, and if, needed) 24 (link)–28 . The same neurosurgeons (BG, JNB) implanted a 1-3-3-1 directional lead (Boston Scientific Vercise DBS system, Natick MA, USA, FDA IDE# G170063) at the STN target under local anesthesia with the patient fully awake. Midazolam 1–2 mg is administered during the placement of the stereotactic frame. Pre-surgical brain MRI scans are co-registered with intraoperative O-arm CT images for STN targeting and to assess micro- and macroelectrode locations. The final DBS location is based on both awake electrophysiology recordings and the co-registered MRI and CT anatomic images. On average, there were 35.2 ± 21.5 days between lead implant and device activation. Participants were allocated to directional or ring stimulation at 2- and 4-month follow-up intervals in a double-blind fashion using block randomization in RedCap using an embedded randomization process. Regardless of directional or ring stimulation, programming goals were to maximize improvements in PD motor symptoms.
Vercise dbs system
Manufactured by Boston Scientific
Sourced in United States
The Vercise DBS system is a deep brain stimulation (DBS) device developed by Boston Scientific. It is designed to deliver electrical stimulation to targeted areas of the brain for the management of neurological conditions. The core function of the Vercise DBS system is to provide adjustable and customizable neurostimulation therapy.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using vercise dbs system
1
Unilateral DBS for Asymmetric PD Symptoms
2
Bilateral STN DBS for Parkinson's Rigidity
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PD patients bilaterally implanted with a Vercise DBS system (Boston Scientific, Valencia, California) in the STN for at least 3 months were included at 4 German centers. All patients had a Unified Parkinson's Disease Rating Scale (UPDRS) subset III score of ≥30 in the preoperative meds‐off state, and ≥30% symptom reduction in the meds‐off state (UPDRS III score) by DBS. To ensure sufficient rigidity to reliably measure a threshold, a meds‐off rigidity score ≥ 2 was required in the evaluated arm (UPDRS III). Patients were excluded if severe tremor would interfere with measurements, defined as meds‐off resting and/or action tremor score ≥3 on the evaluated side (UPDRS III). Patient demographics are shown in Supplementary Table 1.
All sites obtained ethics committee approval. Written informed consent was given by all patients before study inclusion. The study is registered withClinicalTrails.gov (NCT01896115).
All sites obtained ethics committee approval. Written informed consent was given by all patients before study inclusion. The study is registered with
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!